| Objective:Chronic pulmonary heart disease (chronic pulmonary heart disease), referred to as chronic pulmonary heart disease (chronic pulmonale), is from the lung tissue, lung or thoracic vascular changes of chronic lung tissue caused by the structure and (or) dysfunction resulting increase in pulmonary vascular resistance, pulmonary pressure increased,so that the expansion of the right ventricle or (and) hypertrophy, with or without right ventricular heart failure, and the exclusion of congenital heart disease and heart disease caused by those who left.The cause of disease in different parts of the original, can be divided into three categories: bronchial, lung disease,thoracic movement disorders, pulmonary vascular disease, but chronic obstructive pulmonary disease is most common, accounting for about 80%-90%. Modern medicine for chronic pulmonary heart disease a lot of therapy, the treatment methods in addition to incentives for treatment, mainly to reduce pulmonary hypertension in patients to improve pulmonary hypertension caused by right ventricular failure,but because of the scope of clinical use of small and side effects,and can not fundamentally solve the problem. Chinese medicine for chronic pulmonary heart disease awareness has a long history, "Lingshu·Expansion Theory"said: "lung inflation, the true age and cough. ""Lingshu·Meridian"said: "Taiyin hand of pulmonary veins,......... is a dynamic expansion lungdisease is swelling and cough.""Essence phlegm cough·clock card and governance "of the branch described in drink, symptom including" cough on bed, shortness of breath may not be lying, its shape, such as swelling. "cough and be short of air,cann't go to bed"on the pathogenesis of lung inflation: "the lung is injured by cold,so cough; cough is also in the pulmonary interstitial gas is lung expansion, lung inflation is inverse gas, and lung of the empty,gas for the lack of rehabilitation for the evil in high-risk,has not obstruct Chang Sun, the lack of gas also cough", to highlight on the pathogenesis of lung inflation for chronic weak of lung. And the basis of traditional theory,clinical practice, summed up the basis of "a sense of evil is when the standard biased, usually tend to the imaginary" different, selectively chosen andquxie-Fuzheng rule is different.Xuanfei-quxie treatment, reduce gas Huatan, Onyang diuresis, Huoxue-Quyu, cardiopulmonary nourish, such as law Yishen Jianpi.The research is mainly directed against the spleen yang-deficiency in patients with chronic pulmonary heart disease, the use of diuresis Onyang removing the clinical observation of treatment.Methods:1.Tutor in Zhen Wu Tang group based on the cardiac side SHENLONG 1: a report of tablets, ginger, Polyporus, Poria, Alisma, Tinglizi, Motherwort, Chishao, Salvia, Atractylodes macrocephala, Chuanxiong, and the use of modern technology, made them into capsule form to avoid the trouble of the decoction of Chinese medicine and take it with you.2. In my choice of hospital inpatients in 85 cases of kidney-yang deficiency of spleen-type in patients with chronic pulmonary heart disease, aged 60-80 years old in, and randomly divided into treatment group and control group, two cases in terms of gender, age, course of disease, symptoms and signs of respect there was no significant difference (P>0. 05), comparable. Oxygen to the control group, anti-inflammatory, diuretic, antispasmodic asthma, cough Huatan conventional treatment; treatment group therapy in the control group based on the hospital with my home-made traditional Chinese medicine cardiotonic agents on the 1st SHENLONG oral capsules, each 3, 3 times a day. Treatment for 4 weeks as a course of treatment.3. Observed before and after treatment in patients with pulmonary artery systolic pressure, 6-minute walk distance, cardiac function and blood rheology to improve the situation changes. SPSS14. 0 Statistics All data used for statistical analysis software.Results:1. Qiangxin on the 1st capsule in the treatment group and the control group conventional treatment can be effective in improving cardiac function in patients with the treatment group 84. 4% effective rate in the control group 62.5% effective rate,whichever is more significant difference (P<0. 05).See Table 112. On the impact of systolic pulmonary artery pressure in patients: comparison with conventional control group, treatment group patients with a better reduction in systolic pulmonary artery pressure, whichever is more significant difference (P<0. 05). See Table 123. 6 minutes walk from the two groups of comparison: before treatment and compared the treatment group and control group were improved walking distance. But the two groups still have significantdifferences(P<0. 05). Table 134. Hemorrheology two indicators (high shear whole blood viscosity,low shear whole blood viscosity, plasma viscosity, whole blooderythrocyte aggregation index,PaO2, PaCO2) of the comparison,therewas significant differences(P<0. 05),efficacy of the treatmentgroup than the control group. Table 14-19Conclusion:SHENLONG Qiangxin 1 capsule can significantly improve the spleenyang-deficiency type of chronic pulmonary heart disease in patientswith cardiac function and reduce systolic blood pressure inpatients with pulmonary artery to improve blood rheology inpatients with the situation,a certain degree of clinical value, itis worth further clinical research.
|
PDF Full Text Request